In contrast, although genetic alterations in signaling components of TGF-β occur infrequently in various types of cancers, mutations in the Smad4 gene are observed in approximately 60% and 30% of pancreatic and colorectal cancers, respectively. This evidence concerns the gene TGFB1 and cancer.